ClinicalTrials.gg
TerminatedNCT03358407Updated Nov 27, 2020Results posted

GSK2983559 First Time in Human Study

A Phase 1 interventional study of GSK2983559 and Placebo in Inflammatory Bowel Diseases, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was terminated
Terminated due to non clinical toxicology findings and reduced safety margins.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.

Enrollment
56th of 70
31 · median 95
Started
2018
with 8 others
Phase 1
9 of 112
2 open now
Registered
47th of 112
by date
Lead sponsor
9 of 112
GlaxoSmithKline

Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 56th largest by enrollment of the 70 interventional ones that give a count, is one of 9 that started in 2018, is one of 9 in phase 1, and was the 47th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is the first administration of GSK2983559, a selective receptor interacting protein 2 (RIP2) kinase inhibitor, to humans. This will be randomized, double-blinded (sponsor open) and two part study (A and B). Part A of the study is single ascending dose crossover design with two separate cohorts (1 and 2). In Part A, 9 single dose levels will be explored. In Cohort 1, 10 healthy subjects will randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 4:1 in 5 way cross-over design with 5 treatment periods. In Cohort 2, 8 healthy subjects will be randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 3:1 in 4 way cross-overs design with 4 treatment periods. In Cohort 2 there will be an additional period (period 5-open label) for assessing GSK2983559 under fed conditions. There will be 48 hours wash-out period between each dose escalation period. Part B is repeat ascending dose sequential group design. It will contain 4 Cohorts of and dosing will be done sequential dosing. Subjects in Part B will receive once daily (QD) dose or twice daily dose (will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A). There will 58 subjects involved in this study. Total duration of Part A will be approximately for 11 Weeks and Part B will be approximately for 15 Weeks.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Inflammatory Bowel disease
  • Pro-drug
  • Double-blinded
  • Crossover
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 and 65 years of age inclusive, at the time of signing the .
  • Volunteers who are overtly healthy as determined by medical evaluation including medical and psychiatric history, physical examination, neurological examination, clinical laboratory tests and cardiac monitoring.
  • 3Body weight >= 50 kg (kilogram) and (BMI) within the range 19-32 kilogram per meter square (kg/m\^2) .
  • A male subject must agree to use a highly effective during the treatment period and for at least 5 half-lives plus an additional 90 days after the last dose of study treatment and refrain from donating sperm during this period.
  • A female subject is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of (WOCBP)
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participants must agree to avoid prolonged Ultraviolet (UV) exposure to natural sunlight without required Ultraviolet A (UVA)/ Ultraviolet B (UVB) protection or tanning beds for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data.
  • History or current evidence of febrile seizures, epilepsy, convulsions, significant head injury, or other significant neurologic conditions.
  • History of psychiatric disorders as judged by the investigator.
  • Any history of suicidal behavior within the past 6 months or any history of attempted suicide in a subject's lifetime.
  • >1.5x (ULN).
  • >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of Gastrointestinal (GI) surgery (with exception of appendectomy)
  • Average > 450 millisecond (msec)
  • Intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing
  • Live or attenuated vaccine(s) within 30 days of randomization, or plans to receive such vaccines during the study or plans to receive a vaccine within 30 days + 5 half-lives of the last dose of study medication.
  • Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half pint (approximately 240 milliliter [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Current use or history of regular tobacco- or nicotine-containing products within 6 months prior to screening. Subject must have urinary cotinine levels indicative of non-smoking status at screening visit.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an study treatment or any other type of medical research.
  • Subjects with impaired renal function defined as Chronic Kidney Disease Epidemiology Collaboration () calculation \<= 60 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) estimated by the CKD-EPI equation.
  • An elevated C-reactive protein (CRP) outside of the normal reference range.
  • Presence of surface antigen (HBsAg), positive antibody test result at screening or within 3 months prior to first dose of study treatment. As potential for and magnitude of with this compound is unknown, subjects with presence of hepatitis B core antibody (HBcAb) should also be excluded. Subjects positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded.
  • A positive pre-study drug/alcohol screen.
  • A positive test for antibody.
  • A positive diagnostic TB test at screening defined as a positive QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T-spot test is indeterminate, the subject may have the test repeated once, but they will not be eligible for the study unless the second test is negative. In cases where the QuantiFERON or T-spot test is positive, but a locally-read follow up chest x-ray, shows no evidence of current or previous pulmonary tuberculosis, the subject may be eligible for the study at the discretion of the Investigator and GSK Medical Monitor.
  • Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56-day period.
  • Part A (Food Effect) Cohort: Subject must have no dietary restrictions (e.g., lactose intolerance) or inability to eat a high fat meal.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1

    Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.

    Drug: GSK2983559 · Drug: Placebo

  • Experimental
    Part A: Cohort 2 fasting

    Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions

    Drug: GSK2983559 · Drug: Placebo

  • Experimental
    Part A: Cohort 2 fed

    In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.

    Drug: GSK2983559

  • Experimental
    Part B

    Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.

    Drug: GSK2983559 · Drug: Placebo

Interventions

  • DrugGSK2983559

    GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

  • DrugPlacebo

    Placebo oral capsules matching GSK2983559 will be available for subjects.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

    An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

    Time frame: Up to 7 weeks

  2. Part B: Number of Participants With Non-SAEs and SAEs

    An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Non-SAEs and SAEs were planned to be collected.

    Time frame: Up to 11 weeks

  3. Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)

    Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.

    Time frame: Up to 7 weeks

  4. Part B: Number of Participants With Worst Case Hematology Parameters of PCI

    Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.

    Time frame: Up to 11 weeks

  5. Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

    Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\*ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

    Time frame: Up to 7 weeks

  6. Part B: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

    Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.

    Time frame: Up to 11 weeks

  7. Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

    Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.

    Time frame: Up to 7 weeks

  8. Part B: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

    Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.

    Time frame: Up to 11 weeks

  9. Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: 1.5, 2, 2.5, 3, 4, 5, 8, 12, 24 and 48 hours post-dose

  10. Part B: Number of Participants With Abnormal ECG Findings

    12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.

    Time frame: Up to 11 weeks

  11. Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI

    DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

    Time frame: Up to 7 weeks

  12. Part B: Number of Participants With Worst Case DBP and SBP Values of PCI

    DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.

    Time frame: Up to 11 weeks

  13. Part A: Number of Participants With Worst Case Respiration Rate Values of PCI

    Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

    Time frame: Up to 7 weeks

  14. Part B: Number of Participants With Worst Case Respiration Rate Values of PCI

    Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case respiratory rate values of PCI were planned to be evaluated.

    Time frame: Up to 11 weeks

  15. Part A: Number of Participants With Worst Case Heart Rate Values of PCI

    Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

    Time frame: Up to 7 weeks

  16. Part B: Number of Participants With Worst Case Heart Rate Values of PCI

    Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case heart rate values of PCI were planned to be evaluated.

    Time frame: Up to 11 weeks

  17. Part A: Number of Participants With Worst Case Body Temperature Values of PCI

    Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

    Time frame: Up to 7 weeks

  18. Part B: Number of Participants With Worst Case Body Temperature Values of PCI

    Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case body temperature values of PCI were planned to be evaluated.

    Time frame: Up to 11 weeks

  19. Part A: Number of Participants With Abnormal Findings in Physical Examination

    Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.

    Time frame: Up to 7 weeks

  20. Part B: Number of Participants With Abnormal Findings in Physical Examination

    Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.

    Time frame: Up to 11 weeks

  21. Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

    Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours post-dose

  22. Part B: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

    Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and Up to 11 weeks

  23. Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points

    Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours

  24. Part B: Change From Baseline in International Normalized Ratio at Indicated Time Points

    Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and Up to 11 weeks

Secondary outcomes

  1. Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559

    Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  2. Part A (Cohort 2): AUC(0-t) for GSK2983559

    Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  3. Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  4. Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  5. Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  6. Part A (Cohort 2): AUC(0-inf) for GSK2983559

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  7. Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  8. Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  9. Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559

    Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  10. Part A (Cohort 2): Cmax for GSK2983559

    Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  11. Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  12. Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  13. Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559

    Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  14. Part A (Cohort 2): T1/2 for GSK2983559

    Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  15. Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  16. Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  17. Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559

    Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  18. Part A (Cohort 2): Tmax for GSK2983559

    Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  19. Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  20. Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  21. Part B: AUC(0-t) for GSK2983559 Following Single Dose on Day 1

    Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  22. Part B: AUC(0-t) for GSK2983559 on Day 14

    Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  23. Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

    Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  24. Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) on Day 14

    Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  25. Part B: AUC From 0 Hours to the Time of Next Dosing AUC(0-tau) for GSK2983559 Following Single Dose on Day 1

    Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  26. Part B: AUC(0-tau) for GSK2983559 on Day 14

    Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  27. Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

    Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  28. Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) on Day 14

    Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  29. Part B: Cmax for GSK2983559 Following Single Dose on Day 1

    Blood samples were planned to be collected to measure Cmax at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  30. Part B: Cmax for GSK2983559 on Day 14

    Blood samples were planned to be collected to measure Cmax at indicated time-points.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  31. Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

    Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  32. Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14

    Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  33. Part B: Tmax for GSK2983559 Following Single Dose on Day 1

    Blood samples were planned to be collected to measure Tmax at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  34. Part B: Tmax for GSK2983559 on Day 14

    Blood samples were planned to be collected to measure Tmax at indicated time-points.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  35. Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

    Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  36. Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14

    Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  37. Part B: T1/2 for GSK2983559 Following Single Dose on Day 1

    Blood samples were planned to be collected to measure T1/2 at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  38. Part B: T1/2 for GSK2983559 on Day 14

    Blood samples were planned to be collected to measure T1/2 at indicated time-points.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  39. Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

    Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

  40. Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) on Day 14

    Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  41. Part B: Accumulation Ratio of GSK2983559

    Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  42. Part B: Accumulation Ratio of GSK2668176 (Active Moiety of GSK2983559)

    Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

  43. Part A (Cohort 2): AUC (0-t) for GSK2983559 in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  44. Part A (Cohort 2): AUC(0-t) for GSK2983559 in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  45. Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  46. Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  47. Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  48. Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  49. Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  50. Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  51. Part A (Cohort 2): Cmax for GSK2983559 in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  52. Part A (Cohort 2): Cmax for GSK2983559 in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  53. Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  54. Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  55. Part A (Cohort 2): Tmax for GSK2983559 in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  56. Part A (Cohort 2): Tmax for GSK2983559 in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  57. Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  58. Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  59. Part A (Cohort 2): T1/2 for GSK2983559 in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  60. Part A (Cohort 2): T1/2 for GSK2983559 in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

  61. Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

    Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

  62. Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

    Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

    Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

07

Results

Posted Jun 22, 2020

Participant flow

This was a 2-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2983559 in healthy participants. The study was terminated early due to non-clinical toxicology findings and reduced safety margins. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

P1:PartA-Cohort1(4days)+Washout(48hours)
Participant flow — P1:PartA-Cohort1(4days)+Washout(48hours)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started2222200000
Completed2222200000
Not completed0000000000
P2:PartA-Cohort1(4days)+Washout(48hours)
Participant flow — P2:PartA-Cohort1(4days)+Washout(48hours)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started2222200000
Completed2212200000
Not completed0010000000
Withdrew: Adverse event0010000000
P3:PartA-Cohort1(4days)+Washout(48hours)
Participant flow — P3:PartA-Cohort1(4days)+Washout(48hours)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started2222200000
Completed2222200000
Not completed0000000000
P4:PartA-Cohort1(4days)+Washout(48hours)
Participant flow — P4:PartA-Cohort1(4days)+Washout(48hours)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started2222200000
Completed2222100000
Not completed0000100000
Withdrew: Withdrawal by subject0000100000
P5:PartA-Cohort1(4days)+Followup(14days)
Participant flow — P5:PartA-Cohort1(4days)+Followup(14days)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started2222200000
Completed2222200000
Not completed0000000000
P1:PartA-Cohort2(4days)+Washout(48hours)
Participant flow — P1:PartA-Cohort2(4days)+Washout(48hours)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started0000033600
Completed0000002300
Not completed0000031300
Withdrew: Adverse event0000010200
Withdrew: Physician decision0000010100
Withdrew: Withdrawal by subject0000011000
P2:PartA-Cohort2(4days)+Followup(14days)
Participant flow — P2:PartA-Cohort2(4days)+Followup(14days)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started0000033600
Completed0000000000
Not completed0000033600
Withdrew: Study closed/terminated0000033600
Part B: Overall Period (11 Weeks)
Participant flow — Part B: Overall Period (11 Weeks)
MilestonePart A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559
Started0000000000
Completed0000000000
Not completed0000000000

Outcome measures

PrimaryPart A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Non-SAEs62211244
SAEs00000000
PrimaryPart B: Number of Participants With Non-SAEs and SAEs

An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Non-SAEs and SAEs were planned to be collected.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)

Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Hematocrit, To low00000000
Hematocrit, To within range or no change168888899
Hematocrit, To high00000000
Hemoglobin, To low00000000
Hemoglobin, To within range or no change168888899
Hemoglobin, To high00000000
Lymphocytes, To low10000000
Lymphocytes, To within range or no change158888899
Lymphocytes, To high00000000
Platelet count, To low00000000
Platelet count, To within range or no change168888899
Platelet count, To high00000000
Total Neutrophils, To low00000010
Total Neutrophils, To within range or no change168888889
Total Neutrophils, To high00000000
WBC count, To low00000000
WBC count, To within range or no change168888899
WBC count, To high00000000
PrimaryPart B: Number of Participants With Worst Case Hematology Parameters of PCI

Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\*ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
ALT, To low00000000
ALT, To within range or no change168888899
ALT, To high00000000
Albumin, To low00000000
Albumin, To within range or no change168888899
Albumin, To high00000000
ALP, To low00000000
ALP, To within range or no change168888899
ALP, To high00000000
AST, To low00000000
AST, To within range or no change158888899
AST, To high10000000
Calcium, To low00000000
Calcium, To within range or no change168888899
Calcium, To high00000000
Creatinine, To low00000000
Creatinine, To within range or no change168888899
Creatinine, To high00000000
Glucose, To low00000000
Glucose, To within range or no change168888899
Glucose, To high00000000
Potassium, To low00000000
Potassium, To within range or no change168888899
Potassium, To high00000000
Sodium, To low00000000
Sodium, To within range or no change168888899
Sodium, To high00000000
T.bil, To low00000000
T.bil, To within range or no change168888899
T.bil, To high00000000
PrimaryPart B: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method00000000
PrimaryPart B: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings

12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
1.5, 2, 2.5, 3, 4, 5, 8, 12, 24 and 48 hours post-dose
Reported as:
Count of participants · Participants
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,900000001
Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,910000101
Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,900010001
Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 3 hours, n=6,0,0,0,0,0,9,90—————10
Abnormal CS, 3 hours, n=6,0,0,0,0,0,9,90—————00
Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,900110000
Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 5 hours, n=6,0,0,0,0,0,9,90—————02
Abnormal CS, 5 hours, n=6,0,0,0,0,0,9,90—————00
Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,900110101
Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,900000000
Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,900011101
Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,900000000
Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,900000000
Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,900000000
PrimaryPart B: Number of Participants With Abnormal ECG Findings

12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI

DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
DBP, To low00000000
DBP, To within range or no change168888899
DBP, To high00000000
SBP, To low00000000
SBP, To within range or no change168888899
SBP, To high00000000
PrimaryPart B: Number of Participants With Worst Case DBP and SBP Values of PCI

DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Respiration Rate Values of PCI

Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Respiration Rate Values of PCI
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
To low00000000
To within range or no change127687778
To high41201121
PrimaryPart B: Number of Participants With Worst Case Respiration Rate Values of PCI

Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case respiratory rate values of PCI were planned to be evaluated.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Heart Rate Values of PCI

Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Heart Rate Values of PCI
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
To low00000110
To within range or no change168888789
To high00000000
PrimaryPart B: Number of Participants With Worst Case Heart Rate Values of PCI

Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case heart rate values of PCI were planned to be evaluated.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Worst Case Body Temperature Values of PCI

Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Part A: Number of Participants With Worst Case Body Temperature Values of PCI
ParticipantsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
To low00100212
To within range or no change158788687
To high10000000
PrimaryPart B: Number of Participants With Worst Case Body Temperature Values of PCI

Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case body temperature values of PCI were planned to be evaluated.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Number of Participants With Abnormal Findings in Physical Examination

Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.

Time frame:
Up to 7 weeks

No measurements were reported for this outcome.

PrimaryPart B: Number of Participants With Abnormal Findings in Physical Examination

Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.

Time frame:
Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose), 24 and 48 hours post-dose
Reported as:
Mean · Seconds
Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points
SecondsPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
APTT, 24 hours, n=16,8,8,7,8,8,9,90.4 ± 3.350.8 ± 1.832.9 ± 2.85-0.7 ± 1.801.0 ± 1.771.0 ± 2.56-1.3 ± 6.10-1.2 ± 2.11
APTT, 48 hours, n=16,8,8,8,8,8,8,90.5 ± 2.99-0.3 ± 2.660.5 ± 3.070.8 ± 2.380.0 ± 1.692.3 ± 2.71-3.0 ± 6.37-2.4 ± 2.96
PT, 24 hours, n=16,8,8,7,8,8,9,90.1 ± 0.620.3 ± 0.46-0.3 ± 0.460.1 ± 0.69-0.1 ± 0.350.1 ± 0.35-0.2 ± 1.480.0 ± 0.87
PT, 48 hours, n=16,8,8,8,8,8,8,9-0.1 ± 0.340.0 ± 0.53-0.3 ± 0.460.1 ± 0.64-0.1 ± 0.350.1 ± 0.35-0.4 ± 1.510.1 ± 0.93
PrimaryPart B: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and Up to 11 weeks

No measurements were reported for this outcome.

PrimaryPart A: Change From Baseline in International Normalized Ratio at Indicated Time Points

Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose), 24 and 48 hours
Reported as:
Mean · Ratio
Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points
RatioPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
24 hours, n=16,8,8,7,8,8,9,90.001 ± 0.04960.010 ± 0.0278-0.005 ± 0.0404-0.019 ± 0.0430-0.002 ± 0.02820.017 ± 0.0354-0.028 ± 0.1204-0.019 ± 0.0752
48 hours, n=16,8,8,8,8,8,8,9-0.018 ± 0.02480.013 ± 0.0345-0.021 ± 0.0356-0.009 ± 0.0405-0.024 ± 0.02330.020 ± 0.0293-0.035 ± 0.1165-0.020 ± 0.0738
PrimaryPart B: Change From Baseline in International Normalized Ratio at Indicated Time Points

Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and Up to 11 weeks

No measurements were reported for this outcome.

SecondaryPart A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559
Hours*nanogram per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559NA ± NANA ± NANA ± NA1.4088 ± 38.97.2488 ± 63.5
SecondaryPart A (Cohort 2): AUC(0-t) for GSK2983559

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 2): AUC(0-t) for GSK2983559
Hours*nanogram per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): AUC(0-t) for GSK29835598.1765 ± 61.75.9980 ± 67.3
SecondaryPart A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)
Hours*nanogram per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)96.7389 ± 19.3250.6231 ± 36.3390.3911 ± 17.5889.6956 ± 17.22760.8122 ± 41.3
SecondaryPart A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)
Hours*nanogram per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)2608.4326 ± 59.72857.1378 ± 39.9
SecondaryPart A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559
Hours*nanogram per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559NA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2983559

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 2): AUC(0-inf) for GSK2983559
Hours*nanogram per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): AUC(0-inf) for GSK2983559NA ± NANA ± NA
SecondaryPart A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)
Hours*nanogram per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)104.28 ± 19.4257.28 ± 36.0405.39 ± 16.0911.53 ± 17.12860.23 ± 43.0
SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours*nanogram per milliliter
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)
Hours*nanogram per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)2717.46 ± 57.52950.11 ± 38.5
SecondaryPart A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Nanograms per milliliter
Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559
Nanograms per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559NA ± NANA ± NA0.2291 ± 12.40.4034 ± 37.31.1937 ± 40.2
SecondaryPart A (Cohort 2): Cmax for GSK2983559

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Nanograms per milliliter
Part A (Cohort 2): Cmax for GSK2983559
Nanograms per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): Cmax for GSK29835591.3931 ± 69.31.1244 ± 70.0
SecondaryPart A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Nanograms per milliliter
Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)
Nanograms per milliliterPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)10.4980 ± 34.525.9587 ± 38.638.4341 ± 35.593.8714 ± 19.5305.9839 ± 33.0
SecondaryPart A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Nanograms per milliliter
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)
Nanograms per milliliterPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)314.2321 ± 113.3351.0316 ± 68.9
SecondaryPart A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours
Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559
HoursPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559NA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryPart A (Cohort 2): T1/2 for GSK2983559

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours
Part A (Cohort 2): T1/2 for GSK2983559
HoursPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): T1/2 for GSK2983559NA ± NANA ± NA
SecondaryPart A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours
Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)
HoursPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)7.044 ± 33.28.304 ± 26.99.649 ± 26.98.717 ± 23.09.799 ± 24.7
SecondaryPart A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Geometric mean · Hours
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)
HoursPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)10.480 ± 20.49.526 ± 25.6
SecondaryPart A (Cohort 1): Time to Cmax (Tmax) for GSK2983559

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Median · Hours
Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559
HoursPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559NA (NA to NA)NA (NA to NA)4.500 (4.00 to 5.00)4.005 (3.00 to 5.01)4.000 (3.00 to 4.00)
SecondaryPart A (Cohort 2): Tmax for GSK2983559

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Median · Hours
Part A (Cohort 2): Tmax for GSK2983559
HoursPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): Tmax for GSK29835593.506 (3.00 to 6.00)4.000 (3.00 to 5.00)
SecondaryPart A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Median · Hours
Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)
HoursPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mg
Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)3.000 (1.51 to 4.00)2.758 (2.00 to 4.00)4.006 (2.50 to 5.98)4.037 (2.00 to 5.01)3.000 (2.00 to 4.00)
SecondaryPart A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Reported as:
Median · Hours
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)
HoursPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)3.083 (2.00 to 4.00)3.500 (2.00 to 6.00)
SecondaryPart B: AUC(0-t) for GSK2983559 Following Single Dose on Day 1

Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-t) for GSK2983559 on Day 14

Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) on Day 14

Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC From 0 Hours to the Time of Next Dosing AUC(0-tau) for GSK2983559 Following Single Dose on Day 1

Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-tau) for GSK2983559 on Day 14

Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) on Day 14

Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Cmax for GSK2983559 Following Single Dose on Day 1

Blood samples were planned to be collected to measure Cmax at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Cmax for GSK2983559 on Day 14

Blood samples were planned to be collected to measure Cmax at indicated time-points.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Cmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Cmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14

Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Tmax for GSK2983559 Following Single Dose on Day 1

Blood samples were planned to be collected to measure Tmax at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Tmax for GSK2983559 on Day 14

Blood samples were planned to be collected to measure Tmax at indicated time-points.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Tmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Tmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14

Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: T1/2 for GSK2983559 Following Single Dose on Day 1

Blood samples were planned to be collected to measure T1/2 at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: T1/2 for GSK2983559 on Day 14

Blood samples were planned to be collected to measure T1/2 at indicated time-points.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1

Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) on Day 14

Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Accumulation Ratio of GSK2983559

Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart B: Accumulation Ratio of GSK2668176 (Active Moiety of GSK2983559)

Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC (0-t) for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-t) for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Cmax for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Cmax for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Tmax for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Tmax for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): T1/2 for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): T1/2 for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

No measurements were reported for this outcome.

SecondaryPart A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame:
Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

No measurements were reported for this outcome.

Adverse events

Collected over Non-SAEs and SAEs were reported from start of study treatment (Day 1) up to Week 7 for Part A. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo0/16 (0%)0/16 (0%)6/16 (37.5%)
Part A-Cohort 1: GSK2983559 2 mg0/8 (0%)0/8 (0%)2/8 (25%)
Part A-Cohort 1: GSK2983559 4 mg0/8 (0%)0/8 (0%)2/8 (25%)
Part A-Cohort 1: GSK2983559 10 mg0/8 (0%)0/8 (0%)1/8 (12.5%)
Part A-Cohort 1: GSK2983559 30 mg0/8 (0%)0/8 (0%)1/8 (12.5%)
Part A-Cohort 1: GSK2983559 100 mg0/8 (0%)0/8 (0%)2/8 (25%)
Part A-Cohort 2: GSK2983559 200 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
Part A-Cohort 2: GSK2983559 400 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPart A: PlaceboPart A-Cohort 1: GSK2983559 2 mgPart A-Cohort 1: GSK2983559 4 mgPart A-Cohort 1: GSK2983559 10 mgPart A-Cohort 1: GSK2983559 30 mgPart A-Cohort 1: GSK2983559 100 mgPart A-Cohort 2: GSK2983559 200 mgPart A-Cohort 2: GSK2983559 400 mg
PruritusSkin and subcutaneous tissue disorders0/160/80/80/80/80/80/92/9
NasopharyngitisInfections and infestations0/161/80/80/80/81/80/91/9
Tooth abscessInfections and infestations0/160/81/80/80/80/80/90/9
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/160/80/80/80/80/80/90/9
Respiratory tract irritationRespiratory, thoracic and mediastinal disorders0/160/81/80/80/80/80/90/9
Dermatitis contactSkin and subcutaneous tissue disorders0/161/80/80/80/80/80/90/9
Influenza like illnessGeneral disorders2/160/80/80/80/80/80/90/9
Catheter site erythemaGeneral disorders0/160/80/81/80/80/80/90/9
Vessel puncture site painGeneral disorders0/160/81/80/80/80/80/90/9
Arthropod biteInjury, poisoning and procedural complications0/160/80/80/81/80/80/91/9

Baseline characteristics

Only data for Part A is presented as study was terminated during Part A and hence Part B was not initiated.

Age, Continuous
Age, Continuous(Years)Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/ PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559Total
Mean38.0 ± 11.3146.0 ± 14.1452.7 ± 11.8545.5 ± 13.4459.3 ± 4.7342.3 ± 10.5033.8 ± 7.0442.8 ± 11.89——44.2 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/ PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559Total
Female00000000000
Male223236490031
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mgPart A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/PlaceboPart A-Cohort 2: Placebo/GSK 400mgPart A-Cohort 2: GSK 200mg/ PlaceboPart A-Cohort 2: GSK 200mg/GSK 400mgPart B: PlaceboPart B: GSK2983559Total
Black or African American00000010001
Asian - Central/South Asian Heritage00010110003
White - White/Caucasian/European Heritage223135290027
08

Study locations

1 site
  • GSK Investigational Site
    Cambridge, Cambridgeshire CB2 2GG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Feb 2019, 13 months.

Results were first posted in Jun 2020, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Nov 30, 2017
StartActual
Jan 11, 2018
Primary completionActual
Feb 19, 2019
CompletionActual
Feb 19, 2019
Results first posted
Jun 22, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03358407
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Jan 11, 2018
Primary completion
Feb 19, 2019
Completion
Feb 19, 2019
Results posted
Jun 22, 2020
Last update
Nov 27, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion